CDKN2A and neoplasm: Classifying CDKN2A status based on p16 tumor cell expression (0–100%) demonstrated robust performance over a wide range of thresholds, with receiver operating characteristic (ROC) area under the curve (AUC) of 0.993 and 0.997 (blinded and unblinded consensus pathologist p16 scores, respectively) and 0.969 (QuPath p16 score) (Fig. 3).